AzTrials
AzTrials

Infective Endocarditis3D STARSNCT06269679

CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis.

A study testing CBCT in people with Infective Endocarditis, run by Nantes University Hospital at 10 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

1. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Infective Endocarditis
What is being tested?
CBCT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
170 participants
Where
10 sitesFrance
Study dates
18 Dec 2024to 18 Jul 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients hospitalized or recently hospitalized for definite IE according to the 2015 ESC classification, naive patients for dental examination and imaging, whatever the IE responsible microorganism;
  • Patients with a stable clinical state, meaning stabilized IE patients out of the critical phase, compatible with the performance of an OPT and a CBCT;
  • Patients whose life expectancy is expected to be longer than 6 months;
  • Patients who agree to visit the dental department of the hospital to carry out OIF eradication or at his/her personal dentist;
  • Patients over 18 years old;
  • Patients affiliated to a Social Security or a health insurance scheme;
  • Patients who have given informed consent to participate to the study.

Who cannot join

  • OPT or CBCT already performed before the inclusion of the patients in the study and available for the investigator during the patient's hospitalization.
  • Medical contraindications to perform OPT or CBCT imaging;
  • Absence of microbiologic identification of the IE responsible microorganism;
  • Pregnant or breastfeeding women;
  • Patients unable to give informed consent to participate to the study (under trusteeship, guardianship and legal protection).

Trial locations and contacts

10 sites in 1 country. Contact the study team or a site near you to ask about taking part.

10 sites in 1 country

France10 sites, 10 recruiting
  • CHU Bordeaux - Site Pellegrin

    Bordeaux

    Elise ARRIVE, +33/5 56 79 56 79, elise.arrive@u-bordeaux.fr

    Recruiting
  • CHU Clermont-Ferrand

    Clermont-Ferrand

    Magali VIDAL, +33473754405, mvidal@chu-clermontferrand.fr

    Recruiting
  • CHU Grenoble

    Grenoble

    Cécile CHATEL, +33/4 76 76 50 26, cchatel1@chu-grenoble.fr

    Recruiting
  • HCL

    Lyon

    Sarah MILLOT GUARD, +33426680250, sarah.millot-guard@chu-lyon.fr

    Recruiting
  • APHM

    Marseille

    Jean-Hugues CATHERINE, +33676320760, jean-hugues.catherine@ap-hm.fr

    Recruiting
  • CHRU Nancy

    Nancy

    Vanessa MOBY, +33/3 83 39 18 00, vanessa.moby@univ-lorraine.fr

    Recruiting
  • CHU Nantes

    Nantes

    Alexandra CLOITRE, +33/2.40.41.29.85, alexandra.cloitre@univ-nantes.fr

    Astrid GARREAU, astrid.garreau@chu-nantes.fr

    Recruiting
  • AP-HP - Site Bretonneau

    Paris

    MESSECA Clément, +33/1 53 11 18 00, clement.messeca@aphp.fr

    Recruiting
  • CHU Toulouse

    Toulouse

    Sarah COUSTY, +33/5.61.32.20.30, cousty.s@chu-toulouse.fr

    Recruiting
  • CHRU Tours

    Tours

    Frédéric DENIS, +33/2 47 47 47 47, frederic.denis@univ-tours.fr

    Recruiting

Other trials in France

About this study

Official title: 3D Imaging (Cone Beam Computed Tomography) Versus Orthopantomogram on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis: a Multicenter Randomized Superiority Controlled Trial.

  1. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Oral Infectious Foci (OIF) are underdetected using the current recommended clinical examination/Orthopantomogram (OPT) approach; 4. Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF than OPT; 5. To date, no study has been performed to assess the potential benefit of a clinical examination/CBCT approach on the oral health status in IE patients.

Thus, conducting a randomized controlled trial is highly desirable to assess the potential impact of a clinical examination/CBCT approach on the oral health status of patients hospitalized for IE and potentially to reduce IE new episodes.

Being tested
CBCT
Medical subject headings
Endocarditis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CBCTDiagnostic test

    Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.

Study groups in NCT06269679
Study groupRoleWhat they receive
OPTNo interventionOrthopantomogram = current recommended clinical examination approach (comparator procedure)
CBCTExperimentalCone Beam Computed Tomography = experimental clinical examination approach (procedure under evaluation)
Receives: Diagnostic Test: CBCT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Superiority of CBCT

    Number of oral infectious foci detected using orthopantomogram versus Cone Beam Computer Tomography

    Measured: Month 12

  2. Superiority of CBCT

    DFMT index comprising the number of decayed, filled and missing teeth

    Measured: Month 12

  3. Superiority of CBCT

    Number of severe periodontitis sites

    Measured: Month 12

Secondary outcomes (11)
  1. Diagnostic at inclusion

    Determine the diagnostic impact of clinical examination combined with CBCT at inclusion visit (Number of OIF detected at inclusion visit through clinical examination and CBCT versus clinical examination and OPT).

    Measured: Day 0

  2. Incident symptomatic OIF

    Monitor incident symptomatic OIF occuring during the study impacting the initial personalized OIF management (Number of incident symptomatic OIF detected during the study).

    Measured: Month 12

  3. Incident asymptomatic OIF

    Monitor incident asymptomatic OIF occuring during the study i.e. OIF absent at the initial examination but identified at the ultimate visit without symptomatic episode, in patients subjected to a clinical oral examination coupled with a CBCT (Number of incident asymptomatic OIF occuring during the study i.e. OIF absent at the initial examination but detected at the ultimate visit without symptomatic episode, in patients subjected to a clinical oral examination coupled with a CBCT).

    Measured: Month 12

  4. Oral hygiene

    Evaluate the oral hygiene of the IE patients included in the study (Oral hygiene using the Oral Hygiene Index- Simplified score (OHI-S) at inclusion visit and at the end-of-study visit).

    Measured: Day 0 and Month 12

  5. Follow-up habits

    Evaluate the follow-up habits of the IE patients included in the study by number of dental visits per year at inclusion visit and at the end-of-study visit).

    Measured: Day 0 and Month 12

  6. Follow-up habits

    Evaluate the follow-up habits of the IE patients included in the study by number of dental brushings per day (specific questionnaire already validated in French version) at inclusion visit and at the end-of-study visit).

    Measured: Day 0 and Month 12

  7. Oral health quality of life

    Assess the oral health quality of life of the IE patients included in this study (Oral health quality of life using by the short version of the self-administrated Oral Health impact profile-14 questionnaire (OHIP-14), at inclusion visit and at the end-of-study visit).

    Measured: Day 0 and Month 12

  8. Premature end of study

    Analyse the patient's premature end of study (Causes of the patient's premature end of study: loss to follow-up, death, patient withdrawing consent).

    Measured: Month 12

  9. Impact of dental OIF

    Number of dental OIF detected at the end-of-study visit through clinical examination versus number of periodontal OIF detected at the inclusion visit through clinical examination.

    Measured: Month 12

  10. Impact of periodontal OIF

    Number of periodontal OIF detected at the end-of-study visit through clinical examination versus number of periodontal OIF detected at the inclusion visit through clinical examination.

    Measured: Month 12

  11. Impact of mucosal OIF

    Number of mucosal OIF detected at the end-of-study visit through clinical examination versus number of periodontal OIF detected at the inclusion visit through clinical examination.

    Measured: Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2024
  2. Study start18 Dec 2024
  3. Primary completion18 Jul 2028 (estimated)
  4. Study completion18 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
170 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06269679
Sponsor's protocol ID
RC23_0336
Acronym
3D STARS
Status last verified
Oct 2026
First submitted
5 Feb 2024
Last updated
3 Nov 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Cloitre A, Duval X, Boutoille D, Pere M, Garreau A, Fouchard S, Poinas A, Lesclous P. 3D imaging cone beam computed tomography versus orthopantomogram to improve the oral health status of patients hospitalized for infective endocarditis (3D STARS): study protocol of a randomized superiority controlled trial. BMC Oral Health. 2025 Jul 2;25(1):1045. doi: 10.1186/s12903-025-06473-6.

    PubMed 40604829

Questions about this trial

What is this clinical trial studying?

A study testing CBCT in people with Infective Endocarditis, run by Nantes University Hospital at 10 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Superiority of CBCT (time frame: Month 12). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06269679, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in